Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04283539 · ClinicalTrials.gov registry record
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
A clinical trial, sponsored by National Jewish Health.
- Completed
- Registry status
- 255
- Enrollment target
NCT04283539: Completed study, sponsored by National Jewish Health.
NCT04283539 is a clinical trial that has completed, run by National Jewish Health. The registered enrollment target is 255 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04283539 has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- 255 participants
- Enrollment target
Study Summary
This protocol is a prospective, observational study of participants receiving immunotherapy (checkpoint inhibitors, CPI) for cancer therapy, testing the hypothesis that patients with immune related cutaneous adverse events (ircAEs) have unique immunologic endotypes associated with polarized immune responses.
Primary Outcome
cytokines and chemokines
Interventions
- DRUG systemic corticosteroid or biologic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2020-09-23 |
| Est. Completion | 2026-02-28 |
What the finished NCT04283539 record still lists
NCT04283539 is an observational study that tracks outcomes without assigning an intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which systemic corticosteroid or biologic is the first listed.
NCT04283539 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04283539 about?
NCT04283539 is a clinical study titled "Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy". This protocol is a prospective, observational study of participants receiving immunotherapy (checkpoint inhibitors, CPI) for cancer therapy, testing the hypothesis that patients with immune related cutaneous adverse events (ircAEs) have unique immunologic endotypes associated with polarized immune r...
What is the current status of trial NCT04283539?
This trial is currently completed. The enrollment target is 255 participants. The study started on 2020-09-23. Estimated completion is 2026-02-28.
What interventions are being tested in trial NCT04283539?
The interventions under investigation include: systemic corticosteroid or biologic (DRUG).
Who is sponsoring clinical trial NCT04283539?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI